🇺🇸 FDA
Patent

US 12031136

Treatment for skeletal diseases caused by intracellular protein trafficking defects

granted A61KA61K31/155A61K31/16

Quick answer

US patent 12031136 (Treatment for skeletal diseases caused by intracellular protein trafficking defects) held by The Board of Regents of the University of Oklahoma expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Oklahoma
Grant date
Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
3
CPC classes
A61K, A61K31/155, A61K31/16, A61K31/18, A61K31/19